Adpion Extended Release 150 mg (Bupropion Hydrochloride)

Adult dose

Swallow this medication whole. Do not crush, split, or chew it. Doing so may increase the risk of adverse reactions, including seizures. Short-term adjunctive treatment of nicotine dependence during smoking cessation It is recommended to start this medication while the patient is still smoking and to set a “target quit date” within the first 2 weeks after starting treatment, usually in the second week. Administer 150mg once daily for 6 days as the initial dose, then increase to 150mg twice daily. Doses should be taken at least 8 hours apart. The maximum dose per administration should not exceed 150mg, and the total daily dose should not exceed 300mg. Patients should receive this medication for at least 7 weeks. If the patient has not made significant progress toward quitting by week 7 of treatment, they are unlikely to stop smoking during that quit attempt; discontinuation of this medication should be considered. Combination therapy with this medication and a nicotine patch: No dosage adjustment is necessary when this medication is coadministered with a nicotine patch to treat nicotine dependence. Start combination therapy on the target quit date. Before combination treatment, the prescriber should be fully familiar with the prescribing information for this medication and the nicotine patch. Depression Increase the dose gradually to minimize agitation, markedly hyperactive behavior, and insomnia, which are often observed early in treatment. If necessary, the dose may be temporarily reduced, or a sedative-hypnotic with an intermediate or long duration of action may be administered for a short period; however, a sedative-hypnotic is usually not needed after the first week of treatment. Avoiding administration at bedtime may minimize insomnia. If the patient continues to experience distress from adverse reactions, stop increasing the dose. Initial dose: The usual target dose of this medication in adults is 150mg twice daily (300mg/day). Administer 1 tablet once in the morning (150mg/day, 150mg once daily) for at least 4 days. If the patient tolerates it adequately, increase to 1 tablet twice daily (300mg/day, 150mg twice daily), with at least 8 hours between doses. Dose increases above 300mg/day: For patients whose symptoms have not improved after several weeks at 300mg/day, an increase to a maximum of 400mg/day (200mg twice daily) may be considered. Maintenance dose: Long-term efficacy was demonstrated in a study in which patients with recurrent major depression who responded to 8 weeks of acute treatment with this medication were randomized to placebo or the same dose of this medication (150mg twice daily) as maintenance therapy for 44 weeks. Patients should be periodically reevaluated to determine whether maintenance therapy is needed and to identify an appropriate maintenance dose. Patients with hepatic impairment: Use this medication with extreme caution in patients with severe cirrhosis, and do not exceed 100mg per day or 150mg every 2 days in these patients. In patients with mild to moderate cirrhosis, consider reducing the frequency and/or dose. Patients with renal impairment: Consider reducing the frequency and/or dose.

Child dose

The safety and efficacy of this medication in patients under 18 years of age have not been established.

This medication may increase the risk of suicidal thoughts or behaviors in younger individuals with major depression or psychiatric disorders, so careful judgment by a physician is required when using this product. Especially in children and adolescents, safety has not been established and its use is not recommended. When used for smoking cessation, serious psychiatric symptoms such as depressive feelings or suicidal thoughts may occur, so both the patient and the caregiver should observe carefully. There is a risk of seizures with this medication, so it should be avoided or used with extreme caution in patients with a history of seizures or those with factors that may increase their risk of seizures. Dose adjustments are necessary in patients with impaired liver or kidney function, as this medication may accumulate in the body and cause adverse reactions; caution is required. There is limited safety data in patients with cardiovascular disease, so caution is advised when administering this medication. This medication may cause allergic reactions or severe skin hypersensitivity reactions; if symptoms such as rash, itching, or difficulty breathing occur, the medication should be discontinued immediately and a physician should be consulted. Many interactions with other medications can occur, so it's essential to consult a physician before combining with other drugs, especially those that lower the seizure threshold. During treatment, it is advisable to minimize or avoid alcohol consumption, and caution should be taken when driving or operating machinery. Women who are pregnant or planning to become pregnant should discuss the potential effects on the fetus with their physician before administration due to possible influence from this medication. If breastfeeding, consider stopping breastfeeding or discontinuing the medication, as it may be passed to the infant through breast milk. In case of an overdose, seizures, loss of consciousness, and heart irregularities may occur; adherence to the prescribed dosage is critical, and in the event of an overdose, immediate hospital attention is required. This medication is for oral administration only and should be swallowed whole; it should not be chewed or split, as inappropriate administration methods may lead to severe side effects.

Suicidal impulse, suicidal ideation, suicide attempt, depression, anxiety, hostility, aggression, anger, worsening nicotine withdrawal symptoms, nausea, dry mouth, constipation, diarrhea, loss of appetite, oral ulcer, thirst, myalgia, arthralgia, insomnia, abnormal dreams, anxiety, concentration disorder, dizziness, neural irritability, tremors, discomfort, rhinitis, increased cough, pharyngitis, sinusitis, shortness of breath, nosebleed, reaction at patch application site, rash, itching, hives, taste disturbance, tinnitus, headache, infection, weakness, chest pain, pain, fever, hypertension, palpitations, migraine, flashes, vomiting, dysphagia, dystonia, ataxia, Parkinson's syndrome, spasms, inability to cooperate, blood sugar disorder, weight loss, hyponatremia, elevated liver enzyme levels, jaundice, hepatitis, angioedema, bronchospasm, anaphylaxis shock, erythema multiforme, Stevens-Johnson syndrome, visual impairment, frequent urination, urinary retention, fever, fatigue, orthostatic hypotension, syncope, memory impairment, confusion, delusion, paranoid thinking, hallucination, hypersensitivity, depersonalization, decreased appetite, blood sugar disorder, liver dysfunction, bruxism, gastric reflux, gingivitis, glossitis, increased salivation, tongue swelling, colitis, esophagitis, gastrointestinal bleeding, gingival bleeding, liver damage, pancreatitis, gastric ulcer, leg cramps, muscle rigidity, rhabdomyolysis, muscle weakness, coordination abnormalities, decreased libido, discomfort, emotional instability, hyperactivity, excessive muscle tension, sensory loss, suicide, dizziness, amnesia, ataxia, unreality, hypomania, abnormal electroencephalogram, impaired motor function, aphasia, coma, delirium, dysarthria, movement disorder, euphoria, extrapyramidal syndrome, reduced movement, increased libido, manic response, neuralgia, neuropathy, paranoid thinking, suicide attempt, tardive dyskinesia, bronchospasm, pneumonia, erectile dysfunction, polyuria, prostate disorder, abnormal ejaculation, cystitis, dyspareunia, dysuria, gynecomastia, menopause, pain during erection, salpingitis, urinary incontinence, urinary retention, vaginitis, hyperglycemia, hypoglycemia, inappropriate antidiuretic hormone symptoms, edema, peripheral edema, diabetes, petechial hemorrhage, anemia, leukocytosis, leukopenia, lymphadenopathy, pancytopenia, thrombocytopenia, bleeding, thromboembolic complications, maculopapular rash, alopecia, angioedema, exfoliative dermatitis, hirsutism, pupillary control abnormalities, dry eyes, hearing loss, diplopia, increased intraocular pressure, mydriasis, drowsiness, loss of consciousness, conduction disorder, arrhythmia, hallucination, homosexual tachycardia, ECG changes, fever, muscle rigidity, rhabdomyolysis, hypotension, sensory paralysis, coma, respiratory failure, seizures, bradycardia, heart failure, cardiac arrest

This medication is sensitive to light, so it should be stored in a container that does not allow light to enter. Additionally, it is important to store it in a cool place with a temperature below 25 degrees Celsius to maintain effectiveness.

Appearance

A white, round, film-coated tablet that is convex on both sides

Package unit

28 tablets (14 tablets/PTP x 2)